Among the infectious diseases of potential damage to the poultry sector is infectious laryngotracheitis (ILT). Infectious laryngotracheitis is a highly contagious respiratory disease of chickens caused by ILT virus (ILTV), a.k.a Gallid alphaherpesvirus 1 (GaHV-1), which belongs to the genus Iltovirus, subfamily Alphaherpesvirinae, and the family Herpesviridae. The sever form of the disease results in respiratory depression, gasping, and expectoration of bloody exudates with high rates of morbidity and mortality up to 70% in an acute form of infection.

Vaccination and biosecurity are the main strategies for the control of the disease. Live attenuated and recombinant viral vector vaccines are commercially available for use against ILT. Live attenuated vaccines (LAVs) were developed by multiple passages in embryonated eggs recognized as chicken embryo origin (CEO), or by multiple passages in tissue culture recognized as tissue culture origin (TCO). Despite their high effectiveness, GaHV-1 LAVs, particularly the CEO vaccines, carry a high risk of reversion to virulence resulting in outbreaks. The recombinant viral vector vaccines were developed as safest alternatives to the LAVs. Currently, fowl-pox virus (FPV) and herpesvirus of turkeys (HVT) based GaHV-1 vectored vaccines expressing immunogenic proteins of ILTV are widely available on market. Experimental evidence had shown that GaHV-1 viral vector vaccines improve birds’ performance and reduce clinical signs of the disease but are not as effective as CEO and TCO vaccines in diminishing shedding of the challenge virus. Hence, combination strategies of both the recombinant and live ILT vaccines have been practiced in some multiage layer and heavyweight broiler complexes successfully for optimal outcomes.
like a breakthrough now, we have a range of indirect ELISAs for the detection of antibodies directed against Infectious Laryngotracheitis (ILT) in chicken and turkey serum. These tests may be used for disease diagnosis or vaccine monitoring of both conventional and recombinant vaccines thanks to results expressed as titers.

With IDvet’s range of ILT ELISAS, obtain superior test performance and efficiently monitor recombinant vaccines.
The ID Screen® ILT Indirect (ILTS) is perfectly suited for qualitative disease testing, as its improved specificity allows for more reliable results.

The ID Screen® ILTgI Indirect (ILTGIS) is the only commercial ELISA designed to efficiently monitor recombinant vaccines based on gI proteins (rHVT-gI).

The ID Screen ® ILTgB Indirect (ILTGBS) is the only commercial ELISA designed to efficiently monitor recombinant vaccines based on gB proteins (rFP-gB).

Used together, these ELISAs offer DIVA* solutions
You can also ptimize the quality control with the ready-to-use IDvet reference control samples.
These reference samples contain significant levels of antibodies to ILt. The samples are tested undiluted to verify that analytical sensitivity remains constant between runs and operators.